Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation - PubMed (original) (raw)
Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation
S Baqar et al. Clin Diagn Lab Immunol. 1997 May.
Abstract
A sensitive, and at times the most sensitive, measurement of human vaccine immunogenicity is enumeration of antibody-secreting cells (ASC) in peripheral blood. However, this assay, which is inherently capable of measurement of the absolute number of antigen-specific ASC, is not standardized. Thus, quantitative comparison of results between laboratories is not currently possible. To address this issue, isotype-specific ASC were enumerated from paired fresh and cryopreserved mononuclear cell (MNC) preparations from healthy adult volunteers resident in either the United States (US group) or Egypt (EG group). Analysis of fresh cells from US volunteers revealed mean numbers of ASC per 10(6) MNC of 617, 7,738, and 868 for immunoglobulin M (IgM), IgG, and IgA, respectively, whereas EG volunteers had 2,086, 7,580, and 1,677 ASC/10(6) MNC for the respective isotypes. Cryopreservation resulted in a slight reduction in group mean IgM, IgG, and IgA ASC (maximum reduction in group mean, 14%), but in no instance were results obtained with cryopreserved cells significantly lower than those obtained with fresh cells. To determine if cryopreservation affected the number of bacterial antigen-specific ASC detected, cells from a group of US adult volunteers who received a single oral dose of a mutated Escherichia coli heat-labile enterotoxin (LT(R192G)) were tested. There was no significant difference (P > 0.05) in the number of antigen-specific IgA or IgG ASC detected between fresh and cryopreserved MNC. The results support the views that ASC assays can be standardized to yield quantitative results and that the methodology can be changed to make the test more practical.
Similar articles
- Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.
El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, Pasetti MF, Chen WH. El-Kamary SS, et al. Clin Vaccine Immunol. 2013 Nov;20(11):1764-70. doi: 10.1128/CVI.00464-13. Epub 2013 Sep 18. Clin Vaccine Immunol. 2013. PMID: 24049109 Free PMC article. Clinical Trial. - Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine.
Wennerås C, Svennerholm AM, Ahrén C, Czerkinsky C. Wennerås C, et al. Infect Immun. 1992 Jul;60(7):2605-11. doi: 10.1128/iai.60.7.2605-2611.1992. Infect Immun. 1992. PMID: 1612730 Free PMC article. - Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
Lapa JA, Sincock SA, Ananthakrishnan M, Porter CK, Cassels FJ, Brinkley C, Hall ER, van Hamont J, Gramling JD, Carpenter CM, Baqar S, Tribble DR. Lapa JA, et al. Clin Vaccine Immunol. 2008 Aug;15(8):1222-8. doi: 10.1128/CVI.00491-07. Epub 2008 Jun 25. Clin Vaccine Immunol. 2008. PMID: 18579693 Free PMC article. Clinical Trial. - Intestinal immune responses in patients infected with enterotoxigenic Escherichia coli and in vaccinees.
Wennerås C, Qadri F, Bardhan PK, Sack RB, Svennerholm AM. Wennerås C, et al. Infect Immun. 1999 Dec;67(12):6234-41. doi: 10.1128/IAI.67.12.6234-6241.1999. Infect Immun. 1999. PMID: 10569732 Free PMC article. - Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.
Güereña-Burgueño F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova GV, Alving CR, Glenn GM. Güereña-Burgueño F, et al. Infect Immun. 2002 Apr;70(4):1874-80. doi: 10.1128/IAI.70.4.1874-1880.2002. Infect Immun. 2002. PMID: 11895950 Free PMC article.
Cited by
- Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood.
Saletti G, Çuburu N, Yang JS, Dey A, Czerkinsky C. Saletti G, et al. Nat Protoc. 2013 Jun;8(6):1073-87. doi: 10.1038/nprot.2013.058. Epub 2013 May 9. Nat Protoc. 2013. PMID: 23660756 - Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.
Tribble DR, Baqar S, Scott DA, Oplinger ML, Trespalacios F, Rollins D, Walker RI, Clements JD, Walz S, Gibbs P, Burg EF 3rd, Moran AP, Applebee L, Bourgeois AL. Tribble DR, et al. Infect Immun. 2010 Apr;78(4):1750-9. doi: 10.1128/IAI.01021-09. Epub 2010 Jan 19. Infect Immun. 2010. PMID: 20086085 Free PMC article. - Immunology of gut mucosal vaccines.
Pasetti MF, Simon JK, Sztein MB, Levine MM. Pasetti MF, et al. Immunol Rev. 2011 Jan;239(1):125-48. doi: 10.1111/j.1600-065X.2010.00970.x. Immunol Rev. 2011. PMID: 21198669 Free PMC article. Review. - Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.
El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, Pasetti MF, Chen WH. El-Kamary SS, et al. Clin Vaccine Immunol. 2013 Nov;20(11):1764-70. doi: 10.1128/CVI.00464-13. Epub 2013 Sep 18. Clin Vaccine Immunol. 2013. PMID: 24049109 Free PMC article. Clinical Trial. - Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.
Coster TS, Wolf MK, Hall ER, Cassels FJ, Taylor DN, Liu CT, Trespalacios FC, DeLorimier A, Angleberger DR, McQueen CE. Coster TS, et al. Infect Immun. 2007 Jan;75(1):252-9. doi: 10.1128/IAI.01131-06. Epub 2006 Oct 30. Infect Immun. 2007. PMID: 17074855 Free PMC article.
References
- Vaccine. 1995 Jan;13(1):22-8 - PubMed
- Infect Immun. 1995 May;63(5):1617-23 - PubMed
- J Infect Dis. 1996 Jan;173(1):136-41 - PubMed
- Immunology. 1980 Oct;41(2):249-70 - PubMed
- Ann N Y Acad Sci. 1983 Jun 30;409:194-203 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous